ONC – BeOne Medicines Ltd ADR

ONC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.53

Margin Of Safety %

-16

Put/Call OI Ratio

0.76

EPS Next Q Diff

-1.63

EPS Last/This Y

1.81

EPS This/Next Y

0.85

Price

416.57

Target Price

469.12

Analyst Recom

1.28

Performance Q

14.9

Upside

-33.7%

Beta

0.62

Ticker: ONC

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	ONC	374.3	0.62	0.03	1543
2026-10-16	ONC	369.31	0.67	0.69	1476
2026-10-19	ONC	370.36	0.74	0.36	1333
2026-10-20	ONC	384.79	0.74	0.95	1354
2026-10-21	ONC	386.37	0.75	0.62	1410
2026-10-22	ONC	382.59	0.75	0.06	1448
2026-10-23	ONC	377.95	0.58	0.63	1725
2026-10-26	ONC	371.05	0.58	0.50	1746
2026-10-27	ONC	367.05	0.59	2.73	1747
2026-10-28	ONC	373.5	0.60	0.88	1764
2026-10-29	ONC	371.57	0.63	0.00	2059
2026-10-30	ONC	370.29	0.63	0.00	2061
2026-11-02	ONC	361.04	0.63	8.00	2064
2026-11-03	ONC	354.89	0.63	0.08	2066
2026-11-04	ONC	378.19	0.63	1.98	2079
2026-11-05	ONC	387.53	0.97	0.07	3245
2026-11-06	ONC	407.17	0.79	0.80	3633
2026-11-09	ONC	417.6	0.80	1.02	3695
2026-11-10	ONC	424.19	0.80	0.52	3759
2026-11-11	ONC	420.05	0.79	0.14	3848
2026-11-12	ONC	416.07	0.78	0.23	3910
2026-11-13	ONC	416.67	0.76	5.19	4033
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	ONC	375.01	72.3	603.4	7.64
2026-10-16	ONC	368.56	72.3	565.0	7.64
2026-10-19	ONC	370.04	72.3	503.2	7.64
2026-10-20	ONC	370.04	72.3	503.2	7.64
2026-10-21	ONC	384.79	72.3	565.9	7.64
2026-10-22	ONC	382.27	72.3	503.4	7.64
2026-10-23	ONC	377.94	72.3	502.6	7.64
2026-10-26	ONC	369.77	72.7	465.9	7.64
2026-10-27	ONC	366.47	72.7	482.2	7.64
2026-10-28	ONC	373.91	72.7	513.7	7.64
2026-10-29	ONC	370.54	72.7	537.4	7.64
2026-10-30	ONC	369.53	72.7	519.2	7.64
2026-11-02	ONC	362.39	72.7	496.3	7.64
2026-11-03	ONC	355.00	72.7	464.3	7.64
2026-11-04	ONC	377.88	72.7	647.6	7.64
2026-11-05	ONC	388.51	72.7	533.8	7.64
2026-11-06	ONC	407.61	72.7	401.9	7.64
2026-11-09	ONC	418.03	164.0	215.7	7.64
2026-11-10	ONC	424.39	311.1	212.4	7.64
2026-11-11	ONC	420.99	338.7	176.3	7.64
2026-11-12	ONC	416.49	338.7	160.9	7.64
2026-11-13	ONC	416.57	354.2	121.4	9.87
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	ONC	-64.87	1.94	1.86
2026-10-16	ONC	-65.55	1.94	1.86
2026-10-19	ONC	-65.55	1.94	1.86
2026-10-20	ONC	-65.55	1.94	1.86
2026-10-21	ONC	-65.55	1.94	1.86
2026-10-22	ONC	-65.55	1.94	1.86
2026-10-23	ONC	-65.55	1.94	1.86
2026-10-26	ONC	-65.55	1.86	1.86
2026-10-27	ONC	-65.55	1.86	1.73
2026-10-28	ONC	-65.55	1.86	1.73
2026-10-29	ONC	-65.55	1.86	1.73
2026-10-30	ONC	-66.21	1.86	1.73
2026-11-02	ONC	-66.21	2.00	1.73
2026-11-03	ONC	-66.21	2.00	1.73
2026-11-05	ONC	-66.21	2.00	1.73
2026-11-06	ONC	-66.21	2.00	1.73
2026-11-09	ONC	-66.21	1.37	0
2026-11-10	ONC	-66.01	1.37	1.71
2026-11-11	ONC	-66.04	1.37	1.53
2026-11-12	ONC	-66.04	1.37	1.53
2026-11-13	ONC	-66.04	1.37	1.53
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

3.64

Avg. EPS Est. Current Quarter

2.63

Avg. EPS Est. Next Quarter

2.01

Insider Transactions

-66.04

Institutional Transactions

1.37

Beta

0.62

Average Sales Estimate Current Quarter

1878

Average Sales Estimate Next Quarter

1763

Fair Value

350.39

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.9

Max Drawdown 5-Year %

-68.9

Target Price

469.12

P/E

52.81

Forward P/E

38.76

PEG

0.52

P/S

6.62

P/B

8.17

P/Free Cash Flow

30.18

EPS

7.89

Average EPS Est. Cur. Y

9.87

EPS Next Y. (Est.)

10.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.86

Relative Volume

0.46

Return on Equity vs Sector %

-10.7

Return on Equity vs Industry %

8.5

EPS 1 7Days Diff

2.2

EPS 1 30Days Diff

2.23

EBIT Estimation

121.4

◆ ONC Healthcare

$416.54

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

2/20

Pullback

8/25

Volume

8/15

Valuation

9/20

TP/AR

2/10

Options

2/10

RSI

67.5

Range 1M

89.2%

Sup Dist

0.8%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

13/25

Growth

27/30

Estimates

6/20

Inst/Vol

6/15

Options

5/10

EPS Yr

235.1%

EPS NY

21.9%

52W%

95%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🔴 SELL -7.2% upside

Quality

21/30

Valuation

4/30

Growth

22/25

Stability

5/10

LT Trend

1/5

Upside

-7.2%

Quality

MoS

-16%

ONC — P/E HistoricalBiotechnology

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

AMRZ – Amrize Ltd

AMRZ — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

3.22

Margin Of Safety %

-3

Put/Call OI Ratio

1.93

EPS Next Q Diff

-1.25

EPS Last/This Y

0.15

EPS This/Next Y

0.25

Price

40.89

Target Price

45.92

Analyst Recom

2.21

Performance Q

-10.09

Upside

19.4%

Beta

0.04

Ticker: AMRZ

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	AMRZ	37	1.51	23.24	48721
2026-10-16	AMRZ	37.83	1.53	0.30	49198
2026-10-19	AMRZ	37.97	1.88	0.88	42911
2026-10-20	AMRZ	39.16	1.89	5.99	43014
2026-10-21	AMRZ	38.8	1.90	2.74	43406
2026-10-22	AMRZ	39.45	1.91	2.46	43819
2026-10-23	AMRZ	39.44	1.91	5.27	43937
2026-10-26	AMRZ	39.24	1.97	1.43	45581
2026-10-27	AMRZ	40.23	1.95	4.14	46713
2026-10-28	AMRZ	40.05	2.07	0.38	50425
2026-10-29	AMRZ	41.62	1.88	1.41	53297
2026-10-30	AMRZ	41.38	1.90	1.53	53408
2026-11-02	AMRZ	43.32	1.90	0.92	53446
2026-11-03	AMRZ	41.97	1.93	2.27	53305
2026-11-04	AMRZ	44.14	1.96	2.67	54153
2026-11-05	AMRZ	42.67	1.97	1.33	54615
2026-11-06	AMRZ	41.88	1.93	1.29	55018
2026-11-09	AMRZ	42.89	1.95	22.54	55385
2026-11-10	AMRZ	41.98	1.88	0.10	53922
2026-11-11	AMRZ	41.63	1.91	19.05	53655
2026-11-12	AMRZ	40.84	1.93	0.22	54013
2026-11-13	AMRZ	40.9	1.93	1.67	54066
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	AMRZ	37.32	-7.0	505.3	2.43
2026-10-16	AMRZ	37.82	-7.0	485.1	2.42
2026-10-19	AMRZ	37.99	-7.0	469.0	2.42
2026-10-20	AMRZ	37.99	-7.0	469.0	2.42
2026-10-21	AMRZ	38.83	-7.0	509.5	2.42
2026-10-22	AMRZ	39.44	-7.0	489.8	2.42
2026-10-23	AMRZ	39.45	-7.0	460.4	2.42
2026-10-26	AMRZ	39.24	-7.5	442.8	2.42
2026-10-27	AMRZ	40.23	-7.5	493.1	2.42
2026-10-28	AMRZ	40.03	-7.5	483.9	2.42
2026-10-29	AMRZ	41.61	-7.5	516.0	2.42
2026-10-30	AMRZ	41.38	6.7	433.6	2.42
2026-11-02	AMRZ	43.31	6.7	532.7	2.42
2026-11-03	AMRZ	41.97	-2.8	463.2	2.31
2026-11-04	AMRZ	44.15	-4.2	363.9	2.29
2026-11-05	AMRZ	42.65	-4.2	219.6	2.29
2026-11-06	AMRZ	41.87	-4.2	246.5	2.29
2026-11-09	AMRZ	43.04	-4.2	324.5	2.29
2026-11-10	AMRZ	41.90	-4.6	241.6	2.29
2026-11-11	AMRZ	41.63	-4.6	261.9	2.29
2026-11-12	AMRZ	40.83	-4.6	244.7	2.29
2026-11-13	AMRZ	40.89	-4.6	280.4	2.29
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	AMRZ	0.13	2.45	2.43
2026-10-16	AMRZ	0.13	2.45	2.43
2026-10-19	AMRZ	0.13	2.62	2.43
2026-10-20	AMRZ	0.13	2.62	2.43
2026-10-21	AMRZ	0.13	2.62	2.43
2026-10-22	AMRZ	0.13	2.62	2.43
2026-10-23	AMRZ	0.13	2.62	2.43
2026-10-26	AMRZ	0.13	2.28	2.43
2026-10-27	AMRZ	0.13	2.28	2.74
2026-10-28	AMRZ	0.13	2.28	2.74
2026-10-29	AMRZ	0.13	2.28	2.74
2026-10-30	AMRZ	0.13	2.28	2.74
2026-11-02	AMRZ	0.13	2.11	2.74
2026-11-03	AMRZ	0.13	2.11	2.74
2026-11-05	AMRZ	0.13	2.11	2.74
2026-11-06	AMRZ	0.13	2.11	2.74
2026-11-09	AMRZ	0.13	0.63	2.74
2026-11-10	AMRZ	0.13	0.63	2.74
2026-11-11	AMRZ	0.13	0.63	3.22
2026-11-12	AMRZ	0.13	0.63	3.22
2026-11-13	AMRZ	0.13	0.63	3.22
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

1.02

Avg. EPS Est. Current Quarter

0.57

Avg. EPS Est. Next Quarter

-0.23

Insider Transactions

0.13

Institutional Transactions

0.63

Beta

0.04

Average Sales Estimate Current Quarter

2898

Average Sales Estimate Next Quarter

2214

Fair Value

39.84

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

45.92

P/E

18.45

Forward P/E

15.78

PEG

1.36

P/S

1.82

P/B

1.72

P/Free Cash Flow

20.66

EPS

2.22

Average EPS Est. Cur. Y

2.29

EPS Next Y. (Est.)

2.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.93

Relative Volume

0.5

Return on Equity vs Sector %

-7.4

Return on Equity vs Industry %

0.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.15

EBIT Estimation

280.4

◆ AMRZ Basic Materials

$40.91

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

8/20

Pullback

13/25

Volume

8/15

Valuation

13/20

TP/AR

1/10

Options

1/10

RSI

51.6

Range 1M

56.6%

Sup Dist

1.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

12/30

Estimates

2/20

Inst/Vol

3/15

Options

3/10

EPS Yr

9.7%

EPS NY

10.4%

52W%

16.6%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +20% upside

Quality

5/30

Valuation

9/30

Growth

7/25

Stability

5/10

LT Trend

5/5

Upside

+20%

Quality

MoS

-3%

AMRZ — P/E HistoricalBuilding Materials

Amrize Ltd

Sector: Basic Materials

Industry: Building Materials

Employees: 19000

Amrize AG engages in the provision of various building solutions for infrastructure, commercial, and residential construction markets in North America and Canada. It operates through two segments, Building Materials and Building Envelope. The Building Materials segment offers cement and aggregates, as well as ready-mix concrete, asphalt, and other construction materials. The Building Envelope segment provides advanced roofing and wall systems, including single-ply membranes, insulation, shingles, sheathing, waterproofing, and protective coatings; and adhesives, tapes, and sealants. The company was formerly known as Holcim North America Finance Ltd and changed its name to Amrize AG in December 2013. Amrize AG was incorporated in 2023 and is based in Zug, Switzerland.

AMRZ

Latest News

—

Caricamento notizie per AMRZ…

stock quote shares AMRZ – Amrize Ltd Stock Price stock today

news today AMRZ – Amrize Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch AMRZ – Amrize Ltd yahoo finance google finance

stock history AMRZ – Amrize Ltd invest stock market

stock prices AMRZ premarket after hours

ticker AMRZ fair value insiders trading

ADCT – Adc Therapeutics SA

ADCT — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.49

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.02

EPS Last/This Y

-0.03

EPS This/Next Y

0.08

Price

1.34

Target Price

2.62

Analyst Recom

2.2

Performance Q

21.83

Upside

-970.1%

Beta

1.8

Ticker: ADCT

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	ADCT	1.485	0.00	1.00	3108
2026-10-16	ADCT	1.405	0.00	999.99	3109
2026-10-19	ADCT	1.46	0.00	0.00	2585
2026-10-20	ADCT	1.52	0.00	0.00	2789
2026-10-21	ADCT	1.51	0.00	0.00	2791
2026-10-22	ADCT	1.595	0.00	0.00	2791
2026-10-23	ADCT	1.44	0.00	0.00	2796
2026-10-26	ADCT	1.505	0.00	0.00	2818
2026-10-27	ADCT	1.598	0.00	0.00	2818
2026-10-28	ADCT	1.615	0.00	0.00	2818
2026-10-29	ADCT	1.495	0.00	0.00	2743
2026-10-30	ADCT	1.53	0.00	0.00	2743
2026-11-02	ADCT	1.545	0.00	0.00	2703
2026-11-03	ADCT	1.555	0.00	0.00	2707
2026-11-04	ADCT	1.72	0.00	0.00	2425
2026-11-05	ADCT	1.64	0.00	0.00	2425
2026-11-06	ADCT	1.585	0.00	0.00	2425
2026-11-09	ADCT	1.655	0.00	0.00	2476
2026-11-10	ADCT	1.505	0.00	0.00	2476
2026-11-11	ADCT	1.595	0.00	0.00	2515
2026-11-12	ADCT	1.39	0.00	0.00	2515
2026-11-13	ADCT	1.345	0.00	0.00	2571
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	ADCT	1.49	-	-	-0.75
2026-10-16	ADCT	1.40	-	-	-0.75
2026-10-19	ADCT	1.44	-	-	-0.75
2026-10-20	ADCT	1.44	-	-	-0.75
2026-10-21	ADCT	1.53	-	-	-0.75
2026-10-22	ADCT	1.59	-	-	-0.75
2026-10-23	ADCT	1.45	-	-	-0.75
2026-10-26	ADCT	1.50	-	-	-0.75
2026-10-27	ADCT	1.59	-	-	-0.75
2026-10-28	ADCT	1.62	-	-	-0.75
2026-10-29	ADCT	1.50	-	-	-0.75
2026-10-30	ADCT	1.53	-	-	-0.75
2026-11-02	ADCT	1.55	-	-	-0.75
2026-11-03	ADCT	1.55	-	-	-0.75
2026-11-04	ADCT	1.72	-	-	-0.75
2026-11-05	ADCT	1.64	-	-	-0.75
2026-11-06	ADCT	1.58	-	-	-0.75
2026-11-09	ADCT	1.65	-	-	-0.75
2026-11-10	ADCT	1.50	-	-	-0.75
2026-11-11	ADCT	1.60	-	-	-0.75
2026-11-12	ADCT	1.40	-	-	-0.75
2026-11-13	ADCT	1.34	-	-	-0.75
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	ADCT	0.00	-4.03	6.96
2026-10-16	ADCT	0.00	-4.03	6.96
2026-10-19	ADCT	0.00	-4.04	6.96
2026-10-20	ADCT	0.00	-4.04	6.96
2026-10-21	ADCT	0.00	-4.04	6.96
2026-10-22	ADCT	0.00	-4.04	6.96
2026-10-23	ADCT	0.00	-4.04	6.96
2026-10-26	ADCT	0.00	-4.06	6.96
2026-10-27	ADCT	0.00	-4.06	6.40
2026-10-28	ADCT	0.00	-4.06	6.40
2026-10-29	ADCT	0.00	-4.06	6.40
2026-10-30	ADCT	0.00	-4.06	6.40
2026-11-02	ADCT	0.00	-4.14	6.40
2026-11-03	ADCT	0.00	-4.14	6.40
2026-11-05	ADCT	0.00	-4.14	6.40
2026-11-06	ADCT	0.00	-4.14	6.40
2026-11-09	ADCT	0.00	-0.85	6.40
2026-11-10	ADCT	0.00	-0.85	6.40
2026-11-11	ADCT	0.00	-0.85	6.49
2026-11-12	ADCT	0.00	-0.85	6.49
2026-11-13	ADCT	0.00	-0.85	6.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

Institutional Transactions

-0.85

Beta

1.8

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-98.2

Target Price

2.62

P/E

Forward P/E

PEG

P/S

2.02

P/B

P/Free Cash Flow

EPS

-0.53

Average EPS Est. Cur. Y

-0.75

EPS Next Y. (Est.)

-0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-95.73

Relative Volume

0.64

Return on Equity vs Sector %

6.2

Return on Equity vs Industry %

25.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

◆ ADCT Healthcare

$1.34

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

18/25

Volume

9/15

Valuation

12/20

TP/AR

1/10

Options

5/10

RSI

43.4

Range 1M

11.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

19/30

Estimates

0/20

Inst/Vol

3/15

Options

5/10

EPS Yr

37.7%

EPS NY

7.9%

52W%

13.9%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +95.5% upside

Quality

7/30

Valuation

16/30

Growth

16/25

Stability

7/10

LT Trend

3/5

Upside

+95.5%

Quality

ADCT — P/E HistoricalBiotechnology

ADC Therapeutics SA

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 188

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT

Latest News

—

Caricamento notizie per ADCT…

stock quote shares ADCT – Adc Therapeutics SA Stock Price stock today

news today ADCT – Adc Therapeutics SA stock forecast ,stock prediction 2023 2024 2025

marketwatch ADCT – Adc Therapeutics SA yahoo finance google finance

stock history ADCT – Adc Therapeutics SA invest stock market

stock prices ADCT premarket after hours

ticker ADCT fair value insiders trading

CS – Credit Suisse Group AG

UBS – UBS Group AG

UBS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.19

Margin Of Safety %

Put/Call OI Ratio

1.41

EPS Next Q Diff

EPS Last/This Y

1.33

EPS This/Next Y

0.52

Price

48.31

Target Price

53.56

Analyst Recom

2.79

Performance Q

-9.6

Upside

119.5%

Beta

1.18

Ticker: UBS

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	UBS	47.78	1.31	0.69	113343
2026-10-16	UBS	47.68	1.30	2.93	113284
2026-10-19	UBS	46.98	1.35	0.79	104760
2026-10-20	UBS	47.26	1.40	1.86	107265
2026-10-21	UBS	47.92	1.40	0.30	107252
2026-10-22	UBS	46.88	1.38	0.33	107959
2026-10-23	UBS	46.37	1.40	1.98	108671
2026-10-26	UBS	46.47	1.40	1.05	108796
2026-10-27	UBS	46.77	1.40	2.34	109111
2026-10-28	UBS	46.7	1.41	0.58	110265
2026-10-29	UBS	48.15	1.41	0.36	110403
2026-10-30	UBS	47.69	1.40	4.00	110353
2026-11-02	UBS	48.49	1.44	1.20	111716
2026-11-03	UBS	48.01	1.45	0.69	111994
2026-11-04	UBS	50.66	1.45	2.27	112130
2026-11-05	UBS	48.76	1.44	7.19	112980
2026-11-06	UBS	48.27	1.42	1.68	112692
2026-11-09	UBS	48.96	1.41	0.30	112732
2026-11-10	UBS	49.17	1.41	0.13	112900
2026-11-11	UBS	49.37	1.41	0.83	112970
2026-11-12	UBS	48.46	1.41	1.19	113139
2026-11-13	UBS	48.31	1.41	2.87	113172
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	UBS	47.79	5.0	-	3.41
2026-10-16	UBS	47.67	5.0	-	3.41
2026-10-19	UBS	46.97	5.0	-	3.41
2026-10-20	UBS	46.97	5.0	-	3.41
2026-10-21	UBS	47.26	5.0	-	3.41
2026-10-22	UBS	46.87	5.0	-	3.41
2026-10-23	UBS	46.37	5.0	-	3.41
2026-10-26	UBS	46.47	5.0	-	3.41
2026-10-27	UBS	46.78	5.0	-	3.41
2026-10-28	UBS	46.73	5.0	-	3.41
2026-10-29	UBS	48.15	48.2	-	3.41
2026-10-30	UBS	47.69	48.2	-	3.41
2026-11-02	UBS	48.50	48.2	-	3.02
2026-11-03	UBS	48.02	48.2	-	3.24
2026-11-04	UBS	50.66	48.2	-	3.79
2026-11-05	UBS	48.76	48.2	-	3.79
2026-11-06	UBS	47.76	48.2	-	3.79
2026-11-09	UBS	48.96	48.2	-	3.79
2026-11-10	UBS	49.18	48.2	-	3.79
2026-11-11	UBS	49.36	48.2	-	3.79
2026-11-12	UBS	48.45	48.2	-	3.79
2026-11-13	UBS	48.31	48.2	-	3.79
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	UBS	0.00	-2.45	0.21
2026-10-16	UBS	0.00	-2.45	0.21
2026-10-19	UBS	0.00	-2.43	0.21
2026-10-20	UBS	0.00	-2.43	0.21
2026-10-21	UBS	0.00	-2.43	0.21
2026-10-22	UBS	0.00	-2.43	0.21
2026-10-23	UBS	0.00	-2.43	0.21
2026-10-26	UBS	0.00	-2.81	0.21
2026-10-27	UBS	0.00	-2.81	0.21
2026-10-28	UBS	0.00	-2.81	0.21
2026-10-29	UBS	0.00	-2.81	0.21
2026-10-30	UBS	0.00	-2.81	0.21
2026-11-02	UBS	0.00	-2.77	0.21
2026-11-03	UBS	0.00	-2.77	0.21
2026-11-05	UBS	0.00	-2.77	0.21
2026-11-06	UBS	0.00	-2.77	0.21
2026-11-09	UBS	0.00	-1.88	0.21
2026-11-10	UBS	0.00	-1.88	0.21
2026-11-11	UBS	0.00	-1.88	0.19
2026-11-12	UBS	0.00	-1.88	0.19
2026-11-13	UBS	0.00	-1.88	0.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.85

Avg. EPS Est. Current Quarter

0.99

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-1.88

Beta

1.18

Average Sales Estimate Current Quarter

10784

Average Sales Estimate Next Quarter

12034

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

13.7

Max Drawdown 5-Year %

-32.5

Target Price

53.56

P/E

15.94

Forward P/E

11.42

PEG

0.56

P/S

1.82

P/B

1.65

P/Free Cash Flow

EPS

3.03

Average EPS Est. Cur. Y

3.79

EPS Next Y. (Est.)

4.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.07

Relative Volume

0.55

Return on Equity vs Sector %

-1.4

Return on Equity vs Industry %

-0.7

EPS 1 7Days Diff

0.4

EPS 1 30Days Diff

0.43

EBIT Estimation

◆ UBS Financial

$48.31

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

4/20

Pullback

17/25

Volume

8/15

Valuation

9/20

TP/AR

0/10

Options

2/10

RSI

49.2

Range 1M

45.1%

Sup Dist

0.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

16/30

Estimates

1/20

Inst/Vol

1/15

Options

3/10

EPS Yr

33.5%

EPS NY

15.3%

52W%

60.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +154.8% upside

Quality

6/30

Valuation

19/30

Growth

14/25

Stability

2/10

LT Trend

1/5

Upside

+154.8%

Quality

UBS — P/E HistoricalBanks - Diversified

UBS Group AG Registered

Sector: Financial Services

Industry: Banks - Diversified

Employees: 97593

UBS Group AG operates as a wealth manager and bank worldwide. It operates through five segments: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-Core and Legacy. The Global Wealth Management segment offers financial services, advice, and solutions; investment management, estate planning, and corporate advice services; and wealth management and banking products and services to private wealth and institutional customers. Its Personal & Corporate Banking segment provides banking, retirement, financing, investments, and strategic transactions to private, corporate, and institutional customers through its branch network and digital channels in Switzerland. The Asset Management segment offers diversified asset management services. Its Investment Bank segment provides equities, foreign exchange, precious metals, research, advisory, and capital markets services to institutional, corporate, financial sponsor, and Global Wealth Management customers, as well as focused rates and credit platform. The company also offers lending products, such as securities-based lending, mortgages, structured products, and tailored solutions; collateralized lending residential and commercial real estate, primarily against securities, residential and commercial real estate, other real assets (such as ships and aircraft), private market and hedge fund interest; and unsecured lending. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is headquartered in Zurich, Switzerland.

UBS

Latest News

—

Caricamento notizie per UBS…

stock quote shares UBS – UBS Group AG Stock Price stock today

news today UBS – UBS Group AG stock forecast ,stock prediction 2023 2024 2025

marketwatch UBS – UBS Group AG yahoo finance google finance

stock history UBS – UBS Group AG invest stock market

stock prices UBS premarket after hours

ticker UBS fair value insiders trading

STM – STMicroelectronics N.V.

STM — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.19

Margin Of Safety %

Put/Call OI Ratio

0.77

EPS Next Q Diff

0.1

EPS Last/This Y

0.83

EPS This/Next Y

1.27

Price

46.75

Target Price

72.6

Analyst Recom

1.62

Performance Q

-16.22

Upside

-58.1%

Beta

2.01

Ticker: STM

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-15	STM	46.58	0.68	2.98	387875
2026-10-16	STM	45.4	0.68	1.15	389467
2026-10-19	STM	45.61	0.81	0.28	309229
2026-10-20	STM	45.83	0.80	1.61	313416
2026-10-21	STM	47.44	0.79	0.81	314370
2026-10-22	STM	44.08	0.78	0.04	318354
2026-10-23	STM	44.03	0.68	0.16	327168
2026-10-26	STM	45.21	0.71	0.50	313651
2026-10-27	STM	48.68	0.71	0.74	318946
2026-10-28	STM	48.55	0.70	1.29	320387
2026-10-29	STM	50.01	0.74	0.12	339881
2026-10-30	STM	46.75	0.73	1.92	344183
2026-11-02	STM	47.15	0.77	1.40	344925
2026-11-03	STM	48.51	0.79	1.65	350154
2026-11-04	STM	45.58	0.79	0.08	352731
2026-11-05	STM	40.15	0.73	0.82	372494
2026-11-06	STM	41.69	0.73	0.33	375070
2026-11-09	STM	44.51	0.80	0.62	350509
2026-11-10	STM	44.68	0.80	1.28	354523
2026-11-11	STM	46.24	0.80	0.86	357930
2026-11-12	STM	46.45	0.80	0.11	358492
2026-11-13	STM	46.75	0.77	0.07	365468
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-15	STM	46.58	40.8	2149.4	1.34
2026-10-16	STM	45.40	40.8	2244.6	1.34
2026-10-19	STM	45.61	40.8	2329.6	1.34
2026-10-20	STM	45.61	40.8	2329.6	1.34
2026-10-21	STM	45.82	40.8	2328.9	1.34
2026-10-22	STM	44.08	40.8	2107.6	1.34
2026-10-23	STM	44.01	40.8	2311.6	1.34
2026-10-26	STM	45.21	41.4	2391.6	1.34
2026-10-27	STM	48.70	41.4	2542.9	1.34
2026-10-28	STM	48.56	41.4	2308.4	1.34
2026-10-29	STM	50.01	41.4	2408.0	1.34
2026-10-30	STM	46.74	41.4	1654.5	1.34
2026-11-02	STM	47.17	414.8	1869.6	1.37
2026-11-03	STM	48.51	411.2	2008.8	1.14
2026-11-04	STM	45.58	411.2	1728.2	1.14
2026-11-05	STM	39.92	411.2	1565.5	1.14
2026-11-06	STM	41.71	411.2	2016.3	1.14
2026-11-09	STM	44.51	411.2	2105.6	1.14
2026-11-10	STM	44.70	411.2	1916.9	1.36
2026-11-11	STM	46.26	411.2	2008.2	1.36
2026-11-12	STM	46.45	411.2	1918.1	1.36
2026-11-13	STM	46.75	411.2	1923.7	1.36
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-15	STM	0.00	99.15	1.76
2026-10-16	STM	0.00	99.15	1.76
2026-10-19	STM	0.00	102.94	1.76
2026-10-20	STM	0.00	102.94	1.76
2026-10-21	STM	0.00	102.94	1.76
2026-10-22	STM	0.00	102.94	1.76
2026-10-23	STM	0.00	102.94	1.76
2026-10-26	STM	0.00	112.08	1.76
2026-10-27	STM	0.00	112.08	1.25
2026-10-28	STM	0.00	112.08	1.25
2026-10-29	STM	0.00	112.08	1.25
2026-10-30	STM	0.00	112.08	1.25
2026-11-02	STM	0.00	121.01	1.24
2026-11-03	STM	0.00	121.01	1.24
2026-11-05	STM	0.00	121.01	1.24
2026-11-06	STM	0.00	121.01	1.26
2026-11-09	STM	0.00	91.24	0
2026-11-10	STM	0.00	91.24	1.24
2026-11-11	STM	0.00	91.24	1.19
2026-11-12	STM	0.00	91.24	1.19
2026-11-13	STM	0.00	91.24	1.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.37

Avg. EPS Est. Current Quarter

0.56

Avg. EPS Est. Next Quarter

0.47

Insider Transactions

Institutional Transactions

91.24

Beta

2.01

Average Sales Estimate Current Quarter

4158

Average Sales Estimate Next Quarter

3952

Fair Value

63.16

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

42.6

Max Drawdown 5-Year %

-66.7

Target Price

72.6

P/E

83.81

Forward P/E

17.05

PEG

0.18

P/S

3.06

P/B

2.35

P/Free Cash Flow

68.77

EPS

0.56

Average EPS Est. Cur. Y

1.36

EPS Next Y. (Est.)

2.63

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.8

Relative Volume

1.04

Return on Equity vs Sector %

-51.5

Return on Equity vs Industry %

-57.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

1923.7

◆ STM Technology

$46.74

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

15/25

Volume

1/15

Valuation

18/20

TP/AR

1/10

Options

4/10

RSI

49.2

Range 1M

66.4%

Sup Dist

2.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

24/30

Estimates

5/20

Inst/Vol

7/15

Options

8/10

EPS Yr

153.5%

EPS NY

104.1%

52W%

42.2%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +70% upside

Quality

4/30

Valuation

23/30

Growth

18/25

Stability

7/10

LT Trend

0/5

Upside

+70%

Quality

MoS

35%

STM — P/E HistoricalSemiconductors

STMicroelectronics N.V.

Sector: Technology

Industry: Semiconductors

Employees: 49000

STMicroelectronics N.V., together with its subsidiaries, designs, develops, manufactures, and sells semiconductor products in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company operates through Analog products, MEMS and Sensors Group (AM&S); Power and Discrete products (P&D); Embedded Processing (EMP); and RF Products (D&RF) segments. It offers industrial application-specific integrated circuits (ASICs) and application-specific standard products (ASSPs); power management solutions; custom analog ICs, wireless charging solutions; galvanic isolated gate and LED drivers; converters, transistors, intelligent power switches, clocks and timers, comparators, and current-sense amplifiers; micro-electro-mechanical systems (MEMS) sensors, including accelerometers, gyroscopes, magnetic sensors, pressure, temperature, presence detection, biosensors, machine learning, and edge AI processing smart sensors, as well as thermal and piezoelectric actuators; and optical sensing solutions. The company also provides silicon MOSFETs, SiC MOSFETs, IGBTs, thyristors, rectifiers, and power modules and bipolar transistors; microcontrollers, and automotive microcontrollers and secured; radio frequency (RF) communications and ASICs; car infotainment products; ultra-wide band and radar systems; and Connected Security Products; and automotive driver assistance systems. It serves automotive, industrial, personal electronics and communications equipment, and computers and peripherals markets. STMicroelectronics N.V. was incorporated in 1987 and is headquartered in Plan-les-Ouates, Switzerland.

STM

Latest News

—

Caricamento notizie per STM…

stock quote shares STM – STMicroelectronics N.V. Stock Price stock today

news today STM – STMicroelectronics N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch STM – STMicroelectronics N.V. yahoo finance google finance

stock history STM – STMicroelectronics N.V. invest stock market

stock prices STM premarket after hours

ticker STM fair value insiders trading

No more stocks to show

ONC – BeOne Medicines Ltd ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ONC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

AMRZ – Amrize Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AMRZ

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y